Comparative loss of activity of recombinant secretory leukoprotease inhibitor and α 1-protease inhibitor caused by different forms of oxidative stress

European Respiratory Journal

Volumn 10, Issue 9, 1997, Pages 2114-2119

  Vogelmeier, C ^a   Biedermann, T ^a   Maier, K ^b   Mazur, G ^a   Behr, J ^a   Krombach, F ^a   Buhl, R ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

1 protease inhibitor; Inactivation; Reactive oxygen metabolites; Secretory leukoprotease inhibitor; Therapy

Indexed keywords

ALPHA 1 ANTITRYPSIN; REACTIVE OXYGEN METABOLITE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; LUNG; LUNG ALVEOLUS MACROPHAGE; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL;

ALPHA 1-ANTITRYPSIN; ANIMALS; CELLS, CULTURED; CHLORAMINES; HUMANS; LEUKOCYTE ELASTASE; MACACA FASCICULARIS; MACROPHAGES, ALVEOLAR; NEUTROPHILS; OXIDANTS; OXIDATIVE STRESS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SERINE PROTEINASE INHIBITORS; SUCCINIMIDES;

EID: 0030987526     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10092114     Document Type: Article

References (44)

1. 1-proteinase inhibitor in sputum and bronchoalveolar lavage. Hoppe-Seyler's Z Physiol Chem 1984; 365: 587-595.
2. 1-antitrypsin deficiency, emphysema, and liver disease: genetic basis and strategies for therapy. J Clin Invest 1990; 85: 1343-1352.
3. 1-antichymotrypsin. J Biol Chem 1980; 255: 3931-3934.
4. Fritz H. Human mucus proteinase inhibitor (Human MPI). Biol Chem Hoppe-Seyler 1988; 369: 79-82.
5. Birrer P, McElvaney NG, Rüdeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 207-213.
6. Fujita J, Nelson NL, Daughton DM, et al. Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. Am Rev Respir Dis 1990; 142: 57-62.
7. 1-antitrypsin for neutrophil elastase. J Clin Invest 1990; 87: 1060-1065.
8. Cochrane CG, Spragg R, Revak SD. Pathogenesis of the adult respiratory distress syndrome. J Clin Invest 1983; 71: 754-761.
9. 2-macroglobulin. J Clin Invest 1988; 82: 1260-1267.
10. 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062.
11. 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
12. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. J Clin Invest 1992; 90: 1296-1301.
13. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993; 148: 1056-1060.
14. Miller KW, Evans RJ, Eisenberg SP, Thompson RC. Secretory leukocyte protease inhibitor binding to mRNA and DNA as a possible cause of toxicity to Escherichia coli. J Bacteriol 1989; 171: 2166-2172.
15. Eisenberg SP, Hale KK, Heimdal P, Thompson RC. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 1990; 265: 7976-7981.
16. Kohno T, Carmichael DF, Sommer A, Thompson RC. Refolding of recombinant proteins. Meth Enzymol 1990; 185: 187-195.
17. 1-proteinase inhibitor. Biochemistry 1974; 13: 5439-5445.
18. Vogelmeier C, Buhl R, Hoyt RF, et al. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J Appl Physiol 1990; 69: 1843-1848.
19. 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987; 80: 1366-1374.
20. Weiss SJ, Klein R, Slivka A, Wei M. Chlorination of taurine by human neutrophils. J Clin Invest 1982; 70: 598-607.
21. Grisham MB, Jefferson MM, Melton DF, Thomas EL. Chlorination of endogenous amines by isolated neutrophils. J Biol Chem 1984; 259: 10404-10413.
22. Maier K, Leuschel L, Costabel U. Increased levels of oxidized methionine residues in bronchoalveolar lavage fluid proteins from patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 143: 271-274.
23. Krombach F, Fiehl E, Burkhardt D, et al. Short-term and long-term effects of serial bronchoalveolar lavages in a nonhuman primate model. Am J Respir Crit Care Med 1994; 150: 153-158.
24. Suzuki K, Ota K, Sasagawa S, Sakatani T, Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem 1983; 132: 345-352.
25. Armitage P, Berry G. Statistical Methods in Medical Research. 3rd Edn. Oxford, Blackwell Scientific Publications, 1994.
26. Vogelmeier C, Hubbard RC, Fells GA, et al. Anti-neutrophil elastase defence of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 1991; 87: 482-488.
27. Kramps JA, van Twisk CH, Klasen EC, Dijkman JH. Interactions among stimulated human polymorphonuclear leukocytes, released elastase and bronchial antileukoprotease. Clin Science 1988; 75: 53-62.
28. Nadziejko C, Finkelstein I, Balmes JR. Contribution of secretory leukoprotease inhibitor to the antiprotease defence system of the peripheral lung: effect of ozone-induced acute inflammation. Am J Respir Crit Care Med 1995; 152: 1592-1598.
29. Thompson, RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 1986; 83: 6692-6696.
30. 1-proteinase inhibitor. Am J Physiol 1994; 266: L593-L611.
31. 1-proteinase inhibitor. FEBS Letters 1989; 250: 221-226.
32. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 1995; 268: L699-L722.
33. 1-proteinase inhibitor by peroxynitrite. Chem Res Toxicol 1992; 5: 425-431.
34. 1-proteinase inhibitor by alveolar macrophages from healthy smokers requires the presence of myeloperoxidase. Am J Resp Cell Mol Biol 1991; 5: 437-444.
35. Tetley TD. Proteinase imbalance: its role in lung disease. Thorax 1993; 48: 560-565.
36. 1-proteinase inhibitor by human PMN leucocyte collagenase. FEBS letters 1990; 263: 355-357.
37. Estensen RD, White JG, Holmes B. Specific degranulation of human polymorphonuclear leukocytes. Nature 1974; 248: 347-348.
38. 1-proteinase inhibitor in serum by stimulated human polymorphonuclear leukocytes: evidence for a myeloperoxidase-dependent mechanism. Cell Biochemistry and Function 1988; 6: 13-23.
39. 1-proteinase inhibitor in vitro. J Clin Invest 1980; 66: 987-995.
40. 1-antitrypsin. J Biol Chem 1988; 263: 393-397.
41. Kramps JA, van Twisk C, Appelhans H, Meckelein B, Nikiforov T, Dijkman JH. Proteinase inhibitory activities of antileukoprotease are represented by its second COOH-terminal domain. Biochim Biophys Acta 1990; 1038: 178-185.
42. Rudolphus A, Heinzel-Wieland R, Vincent V, et al. Oxidation-resistant variants of recombinant antileukoprotease are better inhibitors of human-neutrophil-elastase-induced emphysema in hamsters than natural recombinant antileukoprotease. Clin Science 1991; 81: 777-784.
43. Stolk J, Heinzel-Wieland R, Saunders D, Dijkman JH, Steffens G. Potency of an oxidation-resistant mutant of secretory leukocyte proteinase inhibitor in lipopolysaccharide-induced emphysema in hamster. Pulmon Pharm 1993; 6: 33-39.
44. Gillissen A, Birrer P, McElvaney NG, et al. Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. J Appl Physiol 1993; 75: 825-832.